Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ReShape Lifesciences, Inc. - Common Stock (NQ:RSLS)

3.920 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ReShape Lifesciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
Hive’s AI- and SMS-based Patient-Self-Service Technology to Manage Prospective Lap-Band® Leads From Initial Contact Through Surgical Consultation 
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
Enhanced Band Reservoir Technology Designed to Improve the Patient Experience 
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
Life Science Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Investor Forum Agenda Announced for June 22nd
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
ReShape Lifesciences® to Participate in Investor and Industry Conferences in June
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update
Conference Call to be Held at 4:30 pm ET on Monday, May 15, 2023 
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference Call
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences Announces Formation of International Scientific Advisory Board
Top Industry Experts in Bariatric Surgery and Obesity Will Help Solidify ReShape’s Position as the Premier Physician-Led Weight Loss and Metabolic Health Solutions Company 
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences® to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
Conference Call to be Held at 8:00 am ET on Wednesday, March 29, 2023 
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences® to Present at the Q2 Virtual Investor Summit
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences(TM) (NASDAQ: RSLS) Featured in Coverage of Investor Summit Group’s Q4 Event
Via Investor Brand Network
News headline image
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Conference Call to be Held at 8:00 am ET Today 
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences Announces $750,000 Registered Direct Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences™ to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
Conference Call to be Held at 8:00 am ET on Monday, November 14, 2022 
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®
Stimulation of Vagus Celiac Fibers with Concurrent High Frequency Alternating Current Block of Hepatic Fibers Decreases Glucose Variability in a Swine Model of Type 2 Diabetes 
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences to Present at the Q4 Investor Summit
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences™ Announces Publication of Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) System in Peer Reviewed, Frontiers in NeuroScience
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences™ Announces Release of a Positive Consensus Statement on Lap-Band® Use and Lap-Band® Aftercare Management by the American Society of Metabolic and Bariatric Surgery (ASMBS)
From ReShape Lifesciences Inc
Via GlobeNewswire
News headline image
ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences(TM) (NASDAQ: RSLS) Featured in Coverage of Investor Summit Group’s Q2 Virtual Event
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.